Patent Conundrum: Ignoring India Will Just Not be Foolhardy, Not An Option Either

The recent verdict of the Supreme Court against Novartis, upholding the decision of the Indian Patent Office (IPO) against grant of patent to their cancer drug Glivec, based on Section 3(d) of the Indian Patents Act, has caused a flutter … Continue reading